Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Verve Therapeutics stock
Learn how to easily invest in Verve Therapeutics stock.
Verve Therapeutics is a biotechnology business based in the US. Verve Therapeutics shares (VERV) are listed on the NASDAQ and all prices are listed in US Dollars. Verve Therapeutics employs 204 staff and has a trailing 12-month revenue of around $1.9 million.
How to buy Verve Therapeutics stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – VERV. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Easy to use platform with $0 stock trading & no annual fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+
Verve Therapeutics stock price (NASDAQ: VERV)Use our graph to track the performance of VERV stocks over time.
Verve Therapeutics shares at a glance
|Latest market close||$14.42|
|52-week range||$10.70 - $43.00|
|50-day moving average||$19.31|
|200-day moving average||$25.41|
|Wall St. target price||$42.60|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-2.91|
Buy Verve Therapeutics stocks from these online trading platformsCompare special offers, low fees and a wide range of investment options among top trading platforms.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Is it a good time to buy Verve Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Verve Therapeutics price performance over time
Historical closes compared with the close of $14.42 from 2023-03-31
|1 week (2023-03-24)||14.42|
|1 month (2023-03-01)||-20.73%|
|3 months (2022-12-30)||-25.48%|
|6 months (2022-09-30)||-58.02%|
|1 year (2022-04-01)||-35.94%|
|2 years (2021-03-28)||N/A|
|3 years (2020-03-28)||N/A|
|5 years (2018-03-28)||N/A|
Verve Therapeutics financials
|Revenue TTM||$1.9 million|
|Gross profit TTM||$-128,154,000|
|Return on assets TTM||-19.48%|
|Return on equity TTM||-34.66%|
|Market capitalisation||$910.7 million|
TTM: trailing 12 months
Verve Therapeutics share dividends
We're not expecting Verve Therapeutics to pay a dividend over the next 12 months.
Verve Therapeutics overview
Verve Therapeutics, Inc. , a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc. ; a development and option agreement with Acuitas Therapeutics, Inc. ; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College.
Verve Therapeutics in the news
Verve Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day
Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates
Frequently asked questionsWhat percentage of Verve Therapeutics is owned by insiders or institutions?
Currently 14.009% of Verve Therapeutics shares are held by insiders and 104.25% by institutions. How many people work for Verve Therapeutics?
Latest data suggests 204 work at Verve Therapeutics. When does the fiscal year end for Verve Therapeutics?
Verve Therapeutics's fiscal year ends in December. Where is Verve Therapeutics based?
Verve Therapeutics's address is: 500 Technology Square, Cambridge, MA, United States, 02139 What is Verve Therapeutics's ISIN number?
Verve Therapeutics's international securities identification number is: US92539P1012
More guides on Finder
Best apps and platforms for ETF investing
The best trading apps come with low fees and are easy to use.
What happens if a brokerage firm fails?
Here’s what happens to your securities if your brokerage fails, and how your assets are protected by SIPC and FDIC.
How to Buy Gold Stocks
Learn about buying physical gold, plus stocks and ETFs, to learn how you can add gold exposure to your portfolio.
Silicon Valley Bank collapse: Which ETFs and stocks are impacted?
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
How to Buy Treasury Bills
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
SVB collapses: What does it mean for your portfolio?
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.
How to buy Vanguard VTI Total Stock Market ETF units
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
Ask an Expert